Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

Halozyme. "We look forward to the study investigators presenting the updated study results at the poster session and ensuing discussion."

Based on the magnitude of response and safety observed in the Phase 1b study, Halozyme announced in April the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. Approximately 124 patients will participate in the study and receive gemcitabine and nab-paclitaxel either with or without PEGPH20. Secondary endpoints of the trial include clinical evaluation of patient response in both treatment arms by tumor biopsy hyaluronan (HA) status.

Halozyme is also developing a HA diagnostic tool that will help evaluate potential treatment benefit based on HA levels for use in the randomized Phase 2 trial. Clinically validating this HA-diagnostic approach in the pancreatic cancer trial may also provide proof-of-concept for use of PEGPH20 in other HA-rich tumor types.

Halozyme Abstracts at ASCO:

  • Poster Presentation/Discussion: (E Hall D1): "A Phase 1b Study of Gemcitabine Plus PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in Patients with Stage IV Previously Untreated Pancreatic Cancer" will be presented by Sunil R. Hingorani M.D ., Ph.D., Fred Hutchinson Cancer Research Center on Monday, June 3 at 1:15PM-5:15PM CDT; discussion from 4:45 PM-5:45PM CDT. (Abstract #4010)
  • Educational Book Abstract: "Pharmacokinetic (PK)/Pharmacodynamic (PD) Results From a Phase 1b Study of PEGylated Hyaluronidase PH20 (PEGPH20) in Combination with Gemcitabine (Gem) in Patients with Pancreatic Cancer" (Abstract # e15005)

*33 percent response rate reported in the ASCO abstract based on partial data available at the time of abstract submission.

About Pancreatic Cancer
In most patients diagnosed with metastat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... for crude 3-D glasses, polarized glasses, and shutter ... devices, used to trick the brain into perceiving ... obsolete with the introduction of new holography technology ... doctoral students Yuval Yifat, Michal Eitan, and Zeev ... nanoantennas that could be used for security as ...
(Date:1/15/2014)... "The interface is the device," Nobel laureate Herbert ... to be found at the junctures where layers ... of nanotechnology, the interfaces between layers of metal ... such high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics ...
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... This webinar will focus on EMA and FDA ... biosimilars. , Regulatory frameworks are evolving many countries to ... complex nature of biopharmaceuticals makes the demonstration of biosimilarity ... Based on the specific aspects of biosimilar drug development ...
Breaking Biology Technology:Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... The U.S. Food and Drug,Administration (FDA) has ... treatment for complicated intra-abdominal and complicated urinary,tract ... a wide range of Gram-positive(1) and Gram-negative(2),bacteria ... serious infections. DORIBAX belongs to a ...
... Oct. 15 It is with great privilege ... of John A.,Elefteriades, M.D., F.A.C.S. to its Board ... W.L. Glenn Professor of Cardiothoracic,Surgery and Chief of ... He serves as Co-Director of the Yale-New Haven ...
... ADELAIDE, Australia, Oct. 15 Ellex Medical Lasers,Limited ... and manufacture of,ophthalmic laser and ultrasound systems, announced ... McGuinness to its board of directors to,underpin the ... and a capital raising in the past twelve ...
Cached Biology Technology:FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 2FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 3FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 4FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 5Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors 2John Marshall and Kevin McGuinness Appointed to Ellex Board 2
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
(Date:7/10/2014)... July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ... Mr. Gino Pereira was interviewed on July 1 ... Tampa Florida . Mr. Pereira discusses the company,s ... Harris and how the Wocket™ aims to replace a ... Cedric Harris tells Gino he has never ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new ... (DW). An Asian OEM has selected FPC1021 for a flagship ... August 2014.   FPC is proud to announce ... planned date for start of mass production in August 2014. ... 5M, for delivery in the first half of July. The ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... test could alter the screening landscape for colorectal cancer, ... Cancer Research special conference on Colorectal Cancer: Biology to ... cancer is the third leading cause of cancer, and ... continue to undergo public colonoscopies in an effort to ...
... October 28, 2010 For Immediate Release A ... the Scripps Translational Science Institute has published a paper ... genetic variations that reveal whether people are predisposed to ... In our modern genetic age, the entire DNA sequences, ...
... team of scientists at the Institut de recherches cliniques ... of the Cytoskeletal Organization and Cell Migration research unit, ... cell motility. Their findings were published online today in ... Press group. This scientific breakthrough could eventually lead to ...
Cached Biology News:New test measures DNA methylation levels to predict colon cancer 2Scientists describe new approach for identifying genetic markers for common diseases 2Scientists describe new approach for identifying genetic markers for common diseases 3A recent IRCM breakthrough impacts cancer research 2
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
... The versatile Promega Flipper® Racks are ... of your small tubes. These polypropylene racks ... choice for freezer storage. They may also ... Each rack is two-sided; one side accommodates ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
...
Biology Products: